- \n
- New IVD automation platform standardizes nucleic acid extraction across diverse assay workflows with improved productivity, sample traceability and process safety<\/b><\/li>\n<\/ul>\n
- \n
- Builds on more than 3,300 cumulative placements of the established QIAsymphony platform while using the same QIAsymphony kits and consumables<\/b><\/li>\n<\/ul>\n
- \n
- Supports high-growth applications such as liquid biopsy<\/b><\/li>\n<\/ul>\n
VENLO, Netherlands & HILDEN, Germany–(BUSINESS WIRE<\/a>)–
\nQIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction.<\/p>\n\nBuilding on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction across diverse assay workflows. The platform delivers highly concentrated DNA and RNA for sensitive downstream assays, supporting reliable detection across clinical molecular testing applications including liquid biopsy, oncology and infectious disease diagnostics.<\/p>\n
\n“Clinical laboratories need automation solutions that combine proven extraction performance with the standardization, traceability and productivity needed for today’s molecular testing workflows,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. \u201cThe commercial launch of QIAsymphony Connect reflects our continued investment in automated sample preparation and strengthens our Sample to Insight portfolio by helping laboratories improve consistency and efficiency across clinical molecular testing.”<\/p>\n
\nQIAGEN has completed the FDA listing in the U.S. and the EUDAMED listing in Europe for QIAsymphony Connect, accomplishing significant regulatory milestones as the platform enters broader commercial availability.<\/p>\n
Advancing routine clinical workflows<\/b><\/p>\n
\nQIAsymphony Connect supports routine clinical molecular testing through following capabilities:<\/p>\n
- \n
- Standardized workflow automation<\/b>: Integrated liquid handling, prefilled IVD reagent cartridges, automated load checks and guided workflow setup minimize run-to-run and operator-to-operator variability, enabling standardized walkaway workflows with less hands-on time while supporting reproducible nucleic acid extraction.\n<\/li>\n<\/ul>\n
- \n
- Complete sample traceability<\/b>: Automated barcode reading of primary sample tubes and eluates, built-in audit trails and onboard process controls provide complete sample traceability and strengthen process safety throughout the extraction workflow.\n<\/li>\n<\/ul>\n
- \n
- High-throughput performance for sensitive molecular testing \u2013 in particular, liquid biopsy<\/b>: Processing of up to 96 samples in four independent batches supports routine laboratory productivity. The novel bead collection and elution approach, together with sample input volumes ranging from a few microliters up to 10 mL, delivers highly concentrated DNA and RNA for sensitive downstream applications. This includes liquid biopsy, which analyzes tumor-derived material circulating in blood and requires sensitive detection of often low-abundance molecular targets, as well as other oncology and infectious disease applications.\n<\/li>\n<\/ul>\n
Supporting existing and new customers<\/b><\/p>\n
\nQIAsymphony Connect introduces enhanced usability, digital connectivity and workflow standardization while maintaining full backward compatibility with trusted QIAsymphony reagent kits and consumables. Their continued use across both platforms facilitates a smoother and faster migration to QIAsymphony Connect.<\/p>\n
\nAt the same time, laboratories implementing new molecular testing applications benefit from workflow enhancements designed to simplify routine operation and support standardized molecular testing.<\/p>\n
\nQIAGEN has already received initial customer orders for QIAsymphony Connect, reflecting early market adoption as the platform enters broader commercial availability.<\/p>\n
\nEarly users have highlighted the platform’s intuitive guided workflow setup, comprehensive sample traceability and reduced hands-on time as important advantages for routine clinical testing. Users also cited the consistency of nucleic acid extraction and simplified run setup as key benefits across both established and newly implemented molecular testing workflows.<\/p>\n
\nLearn more about QIAsymphony Connect at https:\/\/www.qiagen.com\/applications\/automated-sample-preparation\/qiasymphony-connect-overview<\/a>.<\/p>\n
About QIAGEN<\/b><\/p>\n
\nQIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of June 30, 2026, QIAGEN employed about 5,500 people across more than 35 locations. For more information, visit www.qiagen.com<\/a>.<\/p>\n
Forward-Looking Statement<\/b><\/p>\n
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as \u201cbelieve\u201d, \u201chope\u201d, \u201cplan\u201d, \u201cintend\u201d, \u201cseek\u201d, \u201cmay\u201d, \u201cwill\u201d, \u201ccould\u201d, \u201cshould\u201d, \u201cwould\u201d, \u201cexpect\u201d, \u201canticipate\u201d, \u201cestimate\u201d, \u201ccontinue\u201d, \u201ctarget\u201d or other similar words. To the extent that any of the statements contained herein relating to QIAGEN\u2019s products, timing for launch and development, marketing and\/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. These include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN\u2019s products (including fluctuations due to general economic conditions, the level and timing of customers\u2019 funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN\u2019s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors\u2019 products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading \u201cRisk Factors\u201d in our most recent Annual Report on Form 20-F. For further information, please refer to QIAGEN’s filings with the U.S. Securities and Exchange Commission.<\/i><\/p>\n
\nSource: QIAGEN N.V.<\/p>\n
\nCategory: Life Sciences<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260827453017\/en\/<\/a><\/span><\/p>\n
Public Relations
\n<\/b>
e-mail: pr@QIAGEN.com
\n<\/a><\/p>\nInvestor Relations
\n<\/b>
e-mail: ir@QIAGEN.com<\/a><\/p>\nKEYWORDS:<\/b> Europe Germany Netherlands<\/p>\n
INDUSTRY KEYWORDS:<\/b> Biotechnology FDA Health General Health Oncology Health Technology Medical Devices Research Infectious Diseases Science Clinical Trials<\/p>\n
- High-throughput performance for sensitive molecular testing \u2013 in particular, liquid biopsy<\/b>: Processing of up to 96 samples in four independent batches supports routine laboratory productivity. The novel bead collection and elution approach, together with sample input volumes ranging from a few microliters up to 10 mL, delivers highly concentrated DNA and RNA for sensitive downstream applications. This includes liquid biopsy, which analyzes tumor-derived material circulating in blood and requires sensitive detection of often low-abundance molecular targets, as well as other oncology and infectious disease applications.\n<\/li>\n<\/ul>\n
- Complete sample traceability<\/b>: Automated barcode reading of primary sample tubes and eluates, built-in audit trails and onboard process controls provide complete sample traceability and strengthen process safety throughout the extraction workflow.\n<\/li>\n<\/ul>\n
- Standardized workflow automation<\/b>: Integrated liquid handling, prefilled IVD reagent cartridges, automated load checks and guided workflow setup minimize run-to-run and operator-to-operator variability, enabling standardized walkaway workflows with less hands-on time while supporting reproducible nucleic acid extraction.\n<\/li>\n<\/ul>\n
- Supports high-growth applications such as liquid biopsy<\/b><\/li>\n<\/ul>\n
- Builds on more than 3,300 cumulative placements of the established QIAsymphony platform while using the same QIAsymphony kits and consumables<\/b><\/li>\n<\/ul>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260827453017\/en\/639304\/3\/QLogo_20mm_RGB.jpg\")
<\/td>\n<\/tr>\n